Gynecologic Cancers in US 2025
Gynecologic cancers represent a significant health burden for women across the United States, affecting thousands of lives each year and demanding focused attention from healthcare providers, researchers, and public health officials. These cancers affect the female reproductive organs and include five main types: cervical cancer, ovarian cancer, uterine cancer (also called endometrial cancer), vaginal cancer, and vulvar cancer. Each type presents unique challenges in terms of prevention, early detection, and treatment outcomes. Understanding the current landscape of gynecologic cancers is essential for developing effective prevention strategies and improving survival rates among affected women.
The year 2025 marks an important milestone in gynecologic cancer awareness and prevention efforts, particularly with growing evidence of the impact of HPV vaccination programs and advances in screening technologies. According to the Centers for Disease Control and Prevention (CDC), these cancers continue to affect women of all ages, races, and socioeconomic backgrounds, though significant disparities exist in incidence and mortality rates across different demographic groups. The most recent data from the United States Cancer Statistics (USCS) program, which combines information from CDC’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program, provides comprehensive insights into the current state of gynecologic cancers in America. This data reveals both encouraging progress in certain areas and persistent challenges that require continued public health intervention and clinical innovation.
Key Facts and Latest Statistics on Gynecologic Cancers in US 2025
| Statistic Category | Data Point | Source Year |
|---|---|---|
| Total annual gynecologic cancer diagnoses in US | Approximately 84,000 new cases | 2025 |
| Total annual gynecologic cancer deaths in US | Approximately 28,000 deaths | 2025 |
| Most common gynecologic cancer | Uterine cancer (most diagnosed) | 2025 |
| Deadliest gynecologic cancer | Ovarian cancer (highest mortality) | 2025 |
| Cervical cancer new cases annually | Approximately 13,000 cases | 2025 |
| Cervical cancer deaths annually | Approximately 4,000 deaths | 2025 |
| Ovarian cancer status | Second most common gynecologic cancer | 2025 |
| Uterine cancer incidence rate | 24.8 per 100,000 women | 2022 |
| Ovarian cancer incidence rate | 11.4 per 100,000 women | 2022 |
| Cervical cancer incidence rate | 7.5 per 100,000 women | 2022 |
| HPV vaccination rate (ages 13-17) | 76% received at least one dose | 2022 |
| Cervical precancer reduction (ages 20-24) | 79-80% decrease since 2008 | 2022 |
| Latest incidence data available | 2022 (most recent year) | 2025 |
| Latest mortality data available | 2023 (most recent year) | 2025 |
| HPV-associated cancer cases annually | Approximately 49,908 cases | 2022 |
Data source: Centers for Disease Control and Prevention (CDC), United States Cancer Statistics Data Visualizations Tool, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control, June 2025 release.
The latest statistics from the CDC reveal critical insights into the burden of gynecologic cancers across the United States in 2025. The data shows that approximately 84,000 women are diagnosed with gynecologic cancers annually, representing a substantial public health concern that affects communities nationwide. Among these diagnoses, uterine cancer emerges as the most frequently diagnosed gynecologic malignancy with an incidence rate of 24.8 per 100,000 women, making it the fourth most common cancer among American women overall. This is followed by ovarian cancer at 11.4 per 100,000, which, despite being less common than uterine cancer, carries the distinction of being the deadliest gynecologic cancer, causing more deaths than any other cancer of the female reproductive system.
Cervical cancer accounts for approximately 13,000 new cases each year, with a mortality rate of about 4,000 deaths annually. However, cervical cancer represents a unique success story in cancer prevention, as it is the only gynecologic cancer with effective screening tests and is largely preventable through HPV vaccination. The dramatic impact of vaccination programs is evident in recent data showing 79-80% reductions in cervical precancerous lesions among women aged 20-24 between 2008 and 2022. This remarkable decline demonstrates the power of primary prevention strategies. The HPV vaccination rate among adolescents aged 13-17 has reached 76% for at least one dose, though public health officials continue working toward the Healthy People 2030 goal of 80% coverage. These vaccination efforts are critical because HPV-associated cancers account for nearly 49,908 cases annually across both men and women, with gynecologic cancers comprising a significant portion of this burden.
Uterine Cancer Incidence and Mortality Rates in US 2025
| Uterine Cancer Metric | Value | Details |
|---|---|---|
| Annual new diagnoses | Approximately 35,000 cases | Most common gynecologic cancer |
| Incidence rate | 24.8 per 100,000 women | Highest among gynecologic cancers |
| Mortality trend | Increasing by 2% annually | 2008-2018 period |
| Age-standardized mortality rate | 2.787-3.211 per 100,000 | 2019-2022 |
| Highest incidence age group | Women aged 65-69 years | 101.1 per 100,000 in this group |
| Primary affected population | Postmenopausal women | Usually occurs during/after menopause |
| Racial disparity (Black vs White mortality) | 2-fold higher in Black women | 9.1 vs 4.6 per 100,000 |
| Ranking among women’s cancers | Fourth most common cancer | After breast, lung, colorectal |
| Annual percentage change | +6.9% increase | 2013-2022 period |
| Five-year survival rate disparity | Lower for Black women | Even with similar incidence rates |
Data source: Centers for Disease Control and Prevention (CDC), United States Cancer Statistics, CDC WONDER database, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control, 2025.
Uterine cancer has emerged as the most commonly diagnosed gynecologic malignancy in the United States in 2025, with approximately 35,000 new cases diagnosed each year. The incidence rate of 24.8 per 100,000 women positions uterine cancer as the fourth most common cancer among American women, following breast, lung, and colorectal cancers. This cancer predominantly affects women who are going through menopause or are postmenopausal, with the highest incidence rates observed among women aged 65-69 years, where the rate reaches 101.1 per 100,000. Unlike many other cancer types that have shown declining trends, uterine cancer incidence and mortality have been increasing steadily, with an alarming annual percentage change of +6.9% between 2013 and 2022. The age-standardized mortality rate increased from 1.905 per 100,000 in 2010 to 3.211 per 100,000 in 2022, representing a concerning upward trajectory that demands urgent public health attention.
The disparity in uterine cancer outcomes represents one of the most significant racial health inequities in American oncology. Black women experience two-fold higher mortality rates compared to White women, with death rates of 9.1 per 100,000 versus 4.6 per 100,000 respectively, despite having similar incidence rates. This dramatic disparity cannot be explained by disease frequency alone and reflects complex factors including differences in tumor biology, with Black women more frequently presenting with aggressive non-endometrioid subtypes such as serous carcinoma and carcinosarcoma. Additionally, Black women are significantly more likely to present with late-stage disease and experience treatment delays and inequalities in access to specialized gynecologic oncology care. The mortality trend from 2008-2018 showed an increase of 2% annually, and during the COVID-19 pandemic, this trend accelerated further, with excess mortality observed in 2020, 2021, and 2022. These statistics underscore the critical need for enhanced early detection strategies, improved access to quality cancer care for all women regardless of race, and targeted interventions to address the biological and social determinants driving these stark disparities in 2025.
Ovarian Cancer Incidence and Deaths in US 2025
| Ovarian Cancer Metric | Value | Details |
|---|---|---|
| Annual new diagnoses | Approximately 20,890 cases | Estimated for 2025 |
| Annual deaths | Approximately 12,730 deaths | Estimated for 2025 |
| Incidence rate | 11.4 per 100,000 women | Second most common gynecologic cancer |
| Mortality status | Deadliest gynecologic cancer | More deaths than any other reproductive cancer |
| Overall cancer ranking | 11th most common among women | Accounts for 1% of all new cancers |
| Cancer death ranking | Fifth leading cause of cancer death | Among women in US |
| Five-year survival rate | 50.9% overall | Varies greatly by stage at diagnosis |
| Women currently living with diagnosis | Approximately 243,572 women | As of 2022 |
| Lifetime risk of diagnosis | 1 in 91 women | Lifetime probability |
| Lifetime risk of death | 1 in 143 women | Lifetime probability |
| Mortality trend (2010-2019) | -2.8% annual decrease | Annual percentage change |
| Age-standardized mortality rate (2019) | 5.517 per 100,000 | Down from 7.189 in 2010 |
Data source: Centers for Disease Control and Prevention (CDC), United States Cancer Statistics Data Visualizations Tool, American Cancer Society, SEER Program, National Center for Chronic Disease Prevention and Health Promotion, 2025.
Ovarian cancer holds the unfortunate distinction of being the deadliest gynecologic cancer in the United States in 2025, causing more deaths than any other cancer of the female reproductive system despite being only the second most common gynecologic malignancy. An estimated 20,890 women will be diagnosed with ovarian cancer in 2025, and tragically, approximately 12,730 women will die from this disease. The incidence rate of 11.4 per 100,000 women positions ovarian cancer as the 11th most common cancer among women, accounting for approximately 1% of all new cancer cases. However, its impact on mortality is disproportionately high, ranking as the fifth leading cause of cancer-related death among American women. The five-year survival rate of 50.9% reflects the aggressive nature of this disease and the challenges in early detection, as most ovarian cancers are diagnosed after the disease has already metastasized beyond the ovaries.
The burden of ovarian cancer extends beyond annual diagnoses and deaths, with approximately 243,572 women living with a history of ovarian cancer in the United States as of 2022. A woman’s lifetime risk of developing ovarian cancer is 1 in 91, while her lifetime risk of dying from invasive ovarian cancer is 1 in 143. These statistics underscore both the serious nature of the disease and the importance of continued research and improved treatment approaches. On a more positive note, mortality trends show progress, with the age-standardized mortality rate decreasing from 7.189 per 100,000 in 2010 to 5.517 per 100,000 in 2019, representing an annual percentage change of -2.8%. However, this decline in mortality slowed significantly during the COVID-19 pandemic, with the rate of decrease dropping by more than four-fold. Two major challenges persist in ovarian cancer management in 2025: the lack of effective screening tests for early detection and the vague, non-specific symptoms that often delay diagnosis until advanced stages. Most ovarian cancers are discovered after metastasis has occurred, which significantly reduces treatment effectiveness and survival rates, making continued investment in research for early detection methods a critical priority.
Cervical Cancer Statistics and Prevention in US 2025
| Cervical Cancer Metric | Value | Details |
|---|---|---|
| Annual new cases | Approximately 13,000 cases | Diagnosed each year |
| Annual deaths | Approximately 4,000 deaths | Deaths each year |
| Incidence rate | 7.5 per 100,000 women | Third among gynecologic cancers |
| National incidence rate | 7.6 per 100,000 women | Newly diagnosed per year (2021) |
| Most affected age group | Women aged 40-44 years | 14.7 per 100,000 in this group |
| Primary affected population | Women over 30 years old | Most cases occur in this group |
| HPV causation | Approximately 99.7% of cases | Caused by HPV infection |
| Five-year survival rate (overall) | 67.4% | All stages combined |
| Five-year survival rate (early stage) | 91% | When diagnosed early |
| Cervical precancer reduction (ages 20-24) | 79% decrease | CIN2+ lesions, 2008-2022 |
| High-grade precancer reduction (ages 20-24) | 80% decrease | CIN3+ lesions, 2008-2022 |
| Precancer reduction (ages 25-29) | 37% decrease | CIN3+ lesions, 2008-2022 |
| Pap test utilization rate | 83.0% of women | Guideline-consistent testing (past 3 years) |
| Healthy People 2020 target | 93.0% screening goal | Not yet achieved |
Data source: Centers for Disease Control and Prevention (CDC), United States Cancer Statistics, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control, Morbidity and Mortality Weekly Report (MMWR), June 2025.
Cervical cancer represents both a success story and an ongoing challenge in gynecologic cancer prevention in the United States in 2025. Approximately 13,000 new cases are diagnosed annually, with about 4,000 deaths occurring each year, yielding an incidence rate of 7.5 per 100,000 women, making it the third most common gynecologic cancer. What makes cervical cancer unique among gynecologic malignancies is that it is largely preventable through vaccination and is the only gynecologic cancer with recommended screening tests. The disease predominantly affects women over 30 years old, with the highest incidence rate of 14.7 per 100,000 observed among women aged 40-44 years. Remarkably, approximately 99.7% of cervical cancers are caused by untreated or chronic infection with human papillomavirus (HPV), a sexually transmitted virus, making it essentially a vaccine-preventable disease. The five-year survival rate varies dramatically depending on stage at diagnosis, with an overall rate of 67.4% but jumping to an impressive 91% when the cancer is detected at an early stage, emphasizing the critical importance of regular screening.
The impact of HPV vaccination programs on cervical cancer prevention has been nothing short of remarkable in 2025. Among women aged 20-24 years who underwent cervical cancer screening, the incidence of cervical precancerous lesions (CIN2+) decreased by 79% between 2008 and 2022, while higher-grade precancers (CIN3+) decreased by 80% during the same period. Even among women aged 25-29 years, high-grade precancers dropped by 37%. These dramatic reductions directly correlate with increasing HPV vaccination rates since the vaccine’s introduction in 2006, providing powerful evidence of the vaccine’s effectiveness in cancer prevention. Currently, 83.0% of women report guideline-consistent Pap testing within the past three years, though this falls short of the Healthy People 2020 target of 93.0%. Additionally, screening rates show disparities, with Asian women having lower rates at 75.4%, and a concerning downward trend in screening participation observed over the past decade. Despite these challenges, the 2025 data demonstrates that continued investment in HPV vaccination, maintaining high screening rates, and ensuring equitable access to preventive services can substantially reduce cervical cancer burden and move closer to the global goal of cervical cancer elimination.
Vaginal and Vulvar Cancer Incidence in US 2025
| Vaginal and Vulvar Cancer Metric | Value | Details |
|---|---|---|
| Vaginal cancer annual diagnoses | Approximately 1,000 cases | Diagnosed annually |
| Vulvar cancer annual diagnoses | Approximately 3,500 cases | Diagnosed annually |
| Combined percentage of gynecologic cancers | 6-7% of all cases | Relatively uncommon |
| Status among gynecologic cancers | Very rare cancers | Least common types |
| At-risk population | All women | Though incidence is very low |
| HPV causation | Leading cause | For both vaginal and vulvar cancers |
| HPV-negative percentage | Approximately 30% | Of vaginal and vulvar cancers |
| Prevention availability | HPV vaccine effective | Can prevent many cases |
| Screening recommendations | No specific screening tests | Unlike cervical cancer |
| Symptom recognition importance | Critical for early detection | No screening makes awareness vital |
| Treatment characteristics | Often mutilating and traumatic | Surgical treatment can significantly impact quality of life |
| CDC awareness campaign | Inside Knowledge campaign | Educates about symptoms |
Data source: Centers for Disease Control and Prevention (CDC), United States Cancer Statistics Data Visualizations Tool, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control, 2025.
Vaginal and vulvar cancers are the rarest of the five main gynecologic cancer types in the United States in 2025, collectively accounting for only 6-7% of all gynecologic cancer diagnoses. Vaginal cancer is diagnosed in approximately 1,000 women annually, while vulvar cancer affects about 3,500 women each year. Despite their low incidence rates, these cancers present significant challenges for affected women and deserve attention within comprehensive gynecologic cancer prevention and treatment efforts. Like cervical cancer, both vaginal and vulvar cancers are strongly associated with human papillomavirus (HPV) infection, which is the leading cause of these malignancies. However, unlike cervical cancer, approximately 30% of vaginal and vulvar cancers are HPV-negative, suggesting additional causal factors beyond viral infection. All women are at risk for developing these cancers, though the overall probability remains very low compared to other gynecologic cancer types.
A critical challenge in managing vaginal and vulvar cancers in 2025 is the absence of recommended screening tests, unlike the well-established Pap test and HPV testing protocols available for cervical cancer. This lack of screening infrastructure makes symptom awareness and recognition absolutely vital for early detection. The Inside Knowledge campaign by the CDC works to educate women and healthcare providers about the signs and symptoms of all gynecologic cancers, including vaginal and vulvar types. Early symptoms may include unusual vaginal bleeding, discharge, or lumps that should prompt immediate medical evaluation. The HPV vaccine offers significant preventive potential, as it protects against the HPV types that most commonly cause vaginal and vulvar cancers, in addition to cervical cancer. Despite the vaccine being available since 2006, communication about its broader benefits beyond cervical cancer prevention could be enhanced. Treatment for vaginal and vulvar cancers often involves surgical procedures that can be mutilating and traumatic, significantly impacting women’s quality of life, body image, and sexual function, underscoring the importance of prevention through vaccination and early detection through heightened awareness of symptoms.
Racial and Ethnic Disparities in Gynecologic Cancer in US 2025
| Disparity Metric | Black Women | White Women | Disparity Magnitude |
|---|---|---|---|
| Uterine cancer mortality rate | 9.1 per 100,000 | 4.6 per 100,000 | 2-fold higher in Black women |
| Cervical cancer mortality trend (2010-2022) | -2.4% annual decrease | Lower decline rate | Largest decrease among Black women |
| Endometrial cancer mortality disparity | 80% more deaths | Baseline | 80% higher among Black women |
| Overall cancer mortality disparity | 10% higher than White women | Baseline | Despite 9% lower incidence |
| Five-year survival rate | Lower for almost every cancer | Higher baseline | Persistent disparity (2014-2020) |
| Late-stage diagnosis rate | Significantly higher | Lower rate | For breast, lung, colorectal cancers |
| Uterine cancer death rate disparity (trend) | Widening gap | Improving outcomes | Disparity is increasing |
| High-risk uterine cancer subtypes | 2-4 fold higher incidence | Baseline | Serous, carcinosarcoma subtypes |
| Treatment inequalities | Less likely to receive standard care | More likely | Even with same insurance/severity |
| COVID-19 impact | Twice as likely to die | Baseline | Exacerbated disparities |
Data source: Centers for Disease Control and Prevention (CDC), American Cancer Society Cancer Statistics for African American and Black People 2025, National Center for Chronic Disease Prevention and Health Promotion, SEER Program, 2025.
Racial and ethnic disparities in gynecologic cancer outcomes represent one of the most pressing public health challenges in the United States in 2025, with Black women experiencing significantly worse outcomes compared to White women across multiple cancer types. The disparity is particularly stark for uterine cancer, where Black women have a two-fold higher mortality rate of 9.1 per 100,000 compared to 4.6 per 100,000 for White women, despite having similar incidence rates. This means that Black women are dying from uterine cancer at twice the rate of White women even though they develop the disease at comparable frequencies. According to data published by the American Cancer Society, approximately 80% more Black women with endometrial cancer die of their disease each year compared to White women. The disparity extends beyond uterine cancer: overall cancer statistics show that Black women have 10% higher mortality than White women despite having 9% lower incidence, and the five-year survival rate for almost every type of cancer was lower for Black people compared to White people during the 2014-2020 period.
Multiple interconnected factors drive these devastating disparities in 2025. Black women are significantly more likely to present with late-stage disease and are two to four-fold more likely to be diagnosed with high-risk uterine cancer subtypes such as serous carcinoma, carcinosarcoma, and leiomyosarcoma after correcting for hysterectomy prevalence. They also face treatment inequalities, being less likely to receive standard cancer care even when presenting with the same disease severity and having the same insurance status. The COVID-19 pandemic further exacerbated these disparities, with Black individuals being approximately twice as likely to be hospitalized and die from COVID-19 compared to White individuals, and experiencing slower returns to cancer screening and employment. For cervical cancer, mortality rates among Black women decreased by -2.4% annually between 2010 and 2022, representing the largest relative decline among all racial groups, yet disparities persist. The root causes are multifactorial but largely stem from structural racism and inequalities in social determinants of health, including historical practices like redlining, discriminatory housing policies, healthcare access barriers, and implicit bias in medical settings. Addressing these disparities requires comprehensive interventions spanning the entire cancer care continuum, from prevention and screening through treatment and survivorship, along with systemic changes to address social determinants and ensure equitable access to high-quality care.
HPV Vaccination Impact and Coverage in US 2025
| HPV Vaccination Metric | Value | Details |
|---|---|---|
| Adolescent vaccination rate (ages 13-17) | 76% received ≥1 dose | As of 2022 |
| Adolescent vaccination rate (ages 13-17) | 78% received ≥1 dose | As of Centers for Disease Control estimates |
| Healthy People 2030 goal | 80% target | Not yet achieved |
| Recommended vaccination age | Ages 11-12 years | Routine recommendation |
| Catch-up vaccination age | Through age 26 years | For those not vaccinated |
| Optional vaccination age | Ages 27-45 years | Based on shared clinical decision |
| Vaccine type currently used in US | Gardasil-9 (9vHPV) | Protects against 9 HPV types |
| Cervical precancer reduction (ages 20-24) | 79% decrease | CIN2+ lesions, 2008-2022 |
| High-grade precancer reduction (ages 20-24) | 80% decrease | CIN3+ lesions, 2008-2022 |
| HPV-associated cancers preventable annually | 36,400 cancers | Could be prevented by 9vHPV |
| Total HPV-associated cancers annually | 49,908 cases | Both males and females |
| Vaccine effectiveness | >90% prevention of HPV cancers | When given before exposure |
| Protection duration | At least 12 years | No evidence of waning immunity |
Data source: Centers for Disease Control and Prevention (CDC), National Immunization Survey-Teen (NIS-Teen), Morbidity and Mortality Weekly Report (MMWR), United States Cancer Statistics, Healthy People 2030, February-June 2025.
The HPV vaccination program represents one of the most successful cancer prevention initiatives in the United States in 2025, with mounting evidence of substantial real-world impact on reducing cancer-causing infections and precancerous lesions. As of 2022, approximately 76-78% of adolescents aged 13-17 years have received at least one dose of the HPV vaccine, showing steady progress toward the Healthy People 2030 goal of 80% coverage. The CDC recommends routine vaccination at ages 11-12 years, with the vaccine series able to begin as early as age 9. Catch-up vaccination is recommended for all individuals through age 26 who have not been vaccinated, while adults ages 27-45 may decide to get vaccinated after discussing with their healthcare provider. The United States exclusively distributes Gardasil-9 (9vHPV), which protects against nine HPV types including types 6, 11, 16, 18, 31, 33, 45, 52, and 58, offering broad-spectrum protection against the strains responsible for most HPV-related cancers.
The documented impact of HPV vaccination on cervical precancers has been dramatic in 2025. Among women aged 20-24 years who were screened for cervical cancer, the incidence of precancerous lesions (CIN2+) decreased by 79% between 2008 and 2022, while higher-grade precancers (CIN3+) decreased by 80% during the same period. This age group represents the cohort most likely to have been vaccinated as children or adolescents, providing clear evidence of the vaccine’s effectiveness. The percentage of cervical lesions caused by vaccine-preventable HPV types dropped by 40% among vaccinated women since the vaccine’s introduction. Beyond cervical cancer, HPV vaccination has led to significant reductions in genital warts and other HPV-associated cancers, which total approximately 49,908 cases annually in the United States, affecting both males and females. It is estimated that 36,400 HPV-associated cancers could be prevented annually by the 9vHPV vaccine. The vaccine provides more than 90% protection against HPV cancers when administered before exposure to the virus, and protection has been shown to last for at least 12 years with no evidence of waning immunity, supporting the recommendation for early vaccination. As vaccinated cohorts continue to age into older screening groups, further declines in cervical and other HPV-associated cancers are anticipated in coming years.
Gynecologic Cancer Screening and Early Detection in US 2025
| Screening Metric | Value | Details |
|---|---|---|
| Cervical cancer screening rate | 83.0% of women | Guideline-consistent Pap testing (past 3 years) |
| Healthy People 2020 screening goal | 93.0% target | Not achieved, 10 percentage point gap |
| Asian women screening rate | 75.4% | Significantly lower than overall rate |
| Screening trend | Small downward trend | Decrease observed over past decade |
| Recommended Pap test interval | Every 3 years | Cytology only |
| Recommended HPV co-test interval | Every 5 years | When including HPV test |
| Only gynecologic cancer with screening | Cervical cancer | No screening for others |
| Cervical cancer early detection survival | 91% five-year survival | When diagnosed at early stage |
| Cervical cancer overall survival | 67.4% five-year survival | All stages combined |
| National Breast and Cervical Cancer Early Detection Program | 10.4 million screening tests | Provided to 4.2 million women |
| Cervical cancers diagnosed through program | 3,113 invasive cancers | Plus 144,460 premalignant lesions |
| High-grade precancerous lesions detected | 41% were high-grade | Among premalignant lesions found |
Data source: Centers for Disease Control and Prevention (CDC), National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control, National Breast and Cervical Cancer Early Detection Program, Behavioral Risk Factor Surveillance System, 2025.
Cervical cancer screening represents the cornerstone of gynecologic cancer prevention in the United States in 2025, as it is the only gynecologic cancer with recommended screening tests capable of detecting disease in early, highly treatable stages. Currently, 83.0% of women report guideline-consistent Pap testing within the past three years, which involves examining cervical cells for abnormalities that could indicate precancerous changes or cancer. However, this rate falls significantly short of the Healthy People 2020 target of 93.0%, representing a 10 percentage point gap that translates to millions of women not receiving recommended preventive care. Screening rates show notable disparities across racial and ethnic groups, with Asian women having particularly low screening rates at 75.4%. Additionally, a concerning small but significant downward trend has been observed in guideline-consistent screening participation over the past decade, despite the known effectiveness of screening in preventing cervical cancer deaths.
Current screening guidelines recommend that women undergo Pap tests (cytology only) every 3 years, or alternatively, undergo combined Pap and HPV testing every 5 years for more comprehensive screening. The dramatic impact of screening is evident in survival statistics: when cervical cancer is detected at an early stage, the five-year survival rate is 91%, compared to 67.4% overall when all stages are combined. This 23.6 percentage point difference demonstrates the critical importance of early detection through regular screening. The CDC’s National Breast and Cervical Cancer Early Detection Program has been instrumental in expanding access to screening services, particularly for underserved populations. Over its history, the program has provided 10.4 million screening tests to 4.2 million women, resulting in the diagnosis of 3,113 invasive cervical cancers and 144,460 premalignant cervical lesions.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
